

# ***TRAPPC6B* biallelic variants cause a neurodevelopmental disorder with TRAPP II and trafficking disruptions**

Hashem Almousa,<sup>1,†</sup> Sara A. Lewis,<sup>2,3,†</sup> Somayeh Bakhtiari,<sup>2,3</sup> Sandra Hinz Nordlie,<sup>2,3</sup> Alex Pagnozzi,<sup>4</sup> Helen Magee,<sup>2,3</sup> Stephanie Efthymiou,<sup>5</sup> Jennifer A. Heim,<sup>2</sup> Patricia Cornejo,<sup>6,7,8</sup> Maha S. Zaki,<sup>9,10</sup> Najwa Anwar,<sup>11</sup> Shazia Maqbool,<sup>11</sup> Fatima Rahman,<sup>11</sup> Derek E. Neilson,<sup>12</sup> Anusha Vemuri,<sup>13</sup> Sheng Chih Jin,<sup>14</sup> Xiao-Ru Yang,<sup>15</sup> Abolfazl Heidari,<sup>16</sup> Koen van Gassen,<sup>17</sup> Aurélien Trimouille,<sup>18</sup> Christel Thauvin-Robinet,<sup>19,20,21</sup> James Liu,<sup>2,3</sup> Ange-Line Bruel,<sup>20,21</sup> Hoda Tomoum,<sup>22</sup> Mennatallah O. Shata,<sup>22</sup> Mais O. Hashem,<sup>23</sup> Mehran Beiraghi Toosi,<sup>24,25</sup> Ehsan Ghayoor Karimiani,<sup>26</sup> Gözde Yeşil,<sup>27</sup> Lokesh Lingappa,<sup>28</sup> Debangana Baruah,<sup>28</sup> Farnoosh Ebrahimzadeh,<sup>29</sup> Julien Van-Gils,<sup>17</sup> Laurence Faivre,<sup>19</sup> Mina Zamani,<sup>30,31</sup> Hamid Galehdari,<sup>30</sup> Saeid Sadeghian,<sup>32</sup> Gholamreza Shariati,<sup>31,33</sup> Rahema Mohammad,<sup>5</sup> Jasper van der Smagt,<sup>17</sup> Alya Qari,<sup>34</sup> John B. Vincent,<sup>35</sup> A. Micheil Innes,<sup>15</sup> Ali Dursun,<sup>36</sup> R. Köksal Özgül,<sup>36</sup> Halil Tuna Akar,<sup>36</sup> Kaya Bilguvar,<sup>37,38</sup> Cyril Mignot,<sup>39,40</sup> Boris Keren,<sup>39</sup> Claudia Raveli,<sup>41</sup> Lydie Burglen,<sup>42</sup> Alexandra Afenjar,<sup>42</sup> Laura Donker Kaat,<sup>43</sup> Marjon van Slegtenhorst,<sup>43</sup> Fowzan Alkuraya,<sup>23</sup> Henry Houlden,<sup>5</sup> Sergio Padilla-Lopez,<sup>2,3</sup> Reza Maroofian,<sup>5,‡</sup> Michael Sacher<sup>1,44,‡</sup> and Michael C. Kruer<sup>2,3,‡</sup>

<sup>†,‡</sup>**These authors contributed equally to this work.**

## **Abstract**

Highly conserved transport protein particle (TRAPP) complexes regulate subcellular trafficking pathways. Accurate protein trafficking has been increasingly recognized to be critically important for normal development, particularly in the nervous system. Variants in most TRAPP complex subunits have been found to lead to neurodevelopmental disorders with diverse but overlapping phenotypes. We expand on limited prior reports on *TRAPPC6B* with detailed clinical and neuroradiologic assessments, and studies on mechanisms of disease, and new types of variants.

We describe 29 additional patients from 18 independent families with biallelic variants in *TRAPPC6B*. We identified 7 homozygous nonsense (n=12 patients) and 8 canonical splice-site variants (n=17 patients). In addition, we identified one patient with compound heterozygous

1 splice-site/missense variants with a milder phenotype and one patient with homozygous missense  
2 variants.

3 Patients displayed non-progressive microcephaly, global developmental delay/intellectual  
4 disability, epilepsy, and absent expressive language. Movement disorders including stereotypies,  
5 spasticity, and dystonia were also observed. Brain imaging revealed reductions in cortex,  
6 cerebellum, and corpus callosum size with frequent white matter hyperintensity. Volumetric  
7 measurements indicated globally diminished volume rather than specific regional losses.

8 We identified a reduced rate of trafficking into the Golgi apparatus and Golgi  
9 fragmentation in patient-derived fibroblasts that was rescued by wild type TRAPPC6B.  
10 Molecular studies revealed a weakened interaction between mutant TRAPPC6B (c.454C>T,  
11 p.Q152\*) and its TRAPP binding partner TRAPPC3. Patient-derived fibroblasts from the  
12 TRAPPC6B (c.454C>T, p.Q152\*) variant displayed reduced levels of TRAPPC6B as well as  
13 other TRAPP II complex-specific members (TRAPPC9 and TRAPPC10). Interestingly, the  
14 levels of the TRAPPC6B homologue TRAPPC6A were found to be elevated. Moreover, co-  
15 immunoprecipitation experiments showed that TRAPPC6A co-precipitates equally with TRAPP  
16 II and TRAPP III, while TRAPPC6B co-precipitates significantly more with TRAPP II,  
17 suggesting enrichment of the protein in the TRAPP II complex. This implies that variants in  
18 *TRAPPC6B* may preferentially affect TRAPP II functions compared to TRAPP III functions.  
19 Finally, we assessed phenotypes in a *Drosophila TRAPPC6B*-deficiency model. Neuronal  
20 TRAPPC6B knockdown impaired locomotion and led to wing posture defects, supporting a role  
21 for TRAPPC6B in neuromotor function.

22 Our findings confirm the association of damaging biallelic *TRAPPC6B* variants with  
23 microcephaly, intellectual disability, language impairments, and epilepsy. A subset of patients  
24 also exhibited dystonia and/or spasticity with impaired ambulation. These features overlap with  
25 disorders arising from pathogenic variants in other TRAPP subunits, particularly components of  
26 the TRAPP II complex. These findings suggest that TRAPPC6B is essential for brain  
27 development and function, and TRAPP II complex activity may be particularly relevant for  
28 mediating this function.

29

30 **Author affiliations:**

1 1 Concordia University Department of Biology, Montreal, Quebec, H4B1R6, Canada  
2 2 Barrow Neurological Institute, Phoenix Children's Hospital, Phoenix, AZ, 85016, USA  
3 3 Departments of Child Health, Cellular and Molecular Medicine, Genetics, and Neurology,  
4 University of Arizona College of Medicine - Phoenix, Phoenix, AZ, 85004, USA  
5 4 CSIRO Health and Biosecurity, The Australian e-Health Research Centre, Brisbane, 4029,  
6 Australia  
7 5 Department of Neuromuscular Disorders, UCL Queen Square Institute of Neurology, London,  
8 WC1N 3BG, UK  
9 6 Pediatric Neuroradiology Division, Pediatric Radiology, Barrow Neurological Institute,  
10 Phoenix Children's Hospital, Phoenix, AZ, 85016, USA  
11 7 University of Arizona College of Medicine, Phoenix, AZ, 85004, USA  
12 8 Mayo Clinic, Scottsdale, AZ, 85259, USA  
13 9 Clinical Genetics Department, Human Genetics and Genome Research Division, National  
14 Research Centre, Cairo, 12622, Egypt  
15 10 Genetics Department, Armed Forces College of Medicine (AFCM), Cairo, 4460015, Egypt.  
16 11 Department of Developmental-Behavioural Paediatrics, The Children's Hospital and Institute  
17 of Child Health, Lahore, 54000, Pakistan.  
18 12 Genetics and Metabolism, Phoenix Children's Hospital, 85016, Phoenix, AZ, USA  
19 13 Department of Pathology, University of Chicago, Chicago, IL, 60637, USA  
20 14 Department of Genetics, Washington University, St. Louis, MO, 63110, USA  
21 15 Department of Medical Genetics and Alberta Children's Hospital Research Institute,  
22 Cumming School of Medicine, University of Calgary, S.W. Calgary, AB, T2N 4N1, Canada  
23 16 Reference Laboratory of Qazvin Medical University, Qazvin, 34148-33245, Iran  
24 17 Division of Laboratories, Pharmacy and Biomedical Genetics, Section of Clinical Genetics,  
25 University Medical Center Utrecht (UMCU), Utrecht, 3584 CX, Netherlands

- 1 18 Laboratoire de Génétique Moléculaire, Service de Génétique Médicale, CHU Bordeaux -  
2 Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, 33000, France
- 3 19 Department of Genetics and Reference Center for Development disorders and intellectual  
4 disabilities, FHU TRANSLAD, CHU Dijon Bourgogne, Dijon, 21000, France
- 5 20 Unité Fonctionnelle d'Innovation diagnostiques des maladies rares, FHU TRANSLAD, CHU  
6 Dijon Bourgogne, Dijon, 21000, France.
- 7 21 INSERM-Université de Bourgogne UMR1231 GAD "Génétique des Anomalies du  
8 Développement", Dijon, 21078, France
- 9 22 Department of Pediatrics, Ain Shams University, Cairo, 11516, Egypt
- 10 23 Department of Translational Genomics, Center for Genomic Medicine, King Faisal Specialist  
11 Hospital and Research Centre, Riyadh, 11211, Saudi Arabia
- 12 24 Pediatric Neurology Department, Ghaem hospital, Mashhad University of Medical Sciences,  
13 Mashhad, 13944-91388, Iran
- 14 25 Neuroscience Research Center, Mashhad University of Medical Science, Mashhad, 13944-  
15 91388, Iran
- 16 26 Molecular and Clinical Sciences Institute, St. George's, University of London, Cranmer  
17 Terrace, London, SW17 0RE, UK
- 18 27 Istanbul University, Istanbul Medical Faculty Department of Medical Genetics, Istanbul, 34452,  
19 Turkey
- 20 28 Rainbow Children Hospital, Hyderabad, 500034, India
- 21 29 Department of Internal Medicine, Mashhad University of Medical Sciences, Mashhad, 13944-  
22 91388, Iran
- 23 30 Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz,  
24 6135783151, Iran
- 25 31 Narges Medical Genetics and Prenatal Diagnosis Laboratory, Kianpars, Ahvaz, 6155889467,  
26 Iran

- 1 32 Department of Pediatric Neurology, Golestan Medical, Educational, and Research Center,  
2 Ahvaz Jundishapur University of Medical Sciences, Ahvaz, 6135733118, Iran
- 3 33 Department of Medical Genetics, Faculty of Medicine, Ahvaz Jundishapur University  
4 of Medical Sciences, Ahvaz, Iran
- 5 34 Medical Genomics Department, Center for Genomic Medicine, King Faisal Specialist  
6 Hospital and Research Center, Riyadh, 11564, Saudi Arabia.
- 7 35 Molecular Neuropsychiatry & Development (MiND) Lab, Campbell Family Mental Health  
8 Research Institute, Centre for Addiction and Mental Health, Toronto, ON, M6J 1H4, Canada
- 9 36 Hacettepe University, Faculty of Medicine&Institute of Child Health, Department of Pediatric  
10 Metabolism, Ankara, 06800, Turkey
- 11 37 Department of Medical Genetics, Acibadem Mehmet Ali Aydinlar University, Istanbul,  
12 34752, Turkey
- 13 38 Department of Neurosurgery and Genetics, Yale University School of Medicine, New Haven,  
14 CT, 06520, USA
- 15 39 APHP Sorbonne Université, Département de Génétique, Hôpital Trousseau & Groupe  
16 Hospitalier Pitié-Salpêtrière, Paris, 75013, France
- 17 40 Centre de Référence Déficiences Intellectuelles de Causes Rares, Paris, 75012, France
- 18 41 APHP Sorbonne Université, Service de Neuropédiatrie, Hôpital Trousseau, Paris, 75012,  
19 France
- 20 42 Centre de référence des malformations et maladies congénitales du cervelet, Département de  
21 Génétique, APHP. Sorbonne Université, Hôpital Trousseau, 75012, Paris, France
- 22 43 Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, 3000 CA, The  
23 Netherlands.
- 24 44 McGill University Department of Anatomy and Cell Biology, Montreal, Quebec, H3A0C7,  
25 Canada
- 26
- 27 Correspondence to: Associate Professor Michael Kruer

1 Departments of Child Health, Neurology, and Cellular & Molecular Medicine and Program in  
2 Genetics

3 University of Arizona College of Medicine – Phoenix

4 Arizona Biomedical Collaborative Building – 1

5 Phoenix, AZ 85004

6 E-mail: kruerm@arizona.edu

7

8 **Running title:** TRAPPC6B linked to neurodevelopment

9 **Keywords:** TRAPPC6B, NEDMEBA, TRAPPopathy, TRAPP-II complex, ER-golgi trafficking,  
10 Trs33

11

## 12 **Introduction**

13 Trafficking protein particle (TRAPP) complexes regulate vesicle trafficking via guanine  
14 nucleotide exchange factor (GEF) activity of Rab GTPases <sup>1</sup> and localization to compartments  
15 such as the Golgi apparatus <sup>2</sup>. Two TRAPP complexes have been identified in mammals called  
16 TRAPP II and TRAPP III. While both complexes activate Rab1 in vitro <sup>2</sup>, TRAPP II additionally  
17 activates Rab11 <sup>2,3</sup>, a GTPase that also functions in ciliogenesis <sup>4</sup>. TRAPP II proteins have also  
18 been implicated in ciliogenesis <sup>5</sup>. On the other hand, TRAPP III has been implicated in early  
19 secretory pathway traffic and autophagy <sup>6,7</sup>. Knockdowns and mutations in both TRAPP II- and  
20 III-specific proteins have been shown to affect trafficking into and through the Golgi as well as  
21 affecting Golgi morphology <sup>8</sup>. TRAPP-mediated trafficking is crucial for brain development and  
22 function, as variants in multiple TRAPP subunits lead to overlapping neurodevelopmental  
23 disorders, with movement disorders, intellectual disability (ID), epilepsy, and neuromuscular  
24 features (**Table 1**) <sup>8</sup>.

25 Both TRAPP complexes are built upon a common catalytic core of proteins that include  
26 TRAPPC1, TRAPPC2, TRAPPC2L, TRAPPC3, TRAPPC4, TRAPPC5 and TRAPPC6. For the  
27 TRAPP II complex, TRAPPC9 and TRAPPC10 are linked to the core while the TRAPP III  
28 complex contains the core with TRAPPC8, TRAPPC11 and TRAPPC12 <sup>6,9,10</sup>. Two genes

1 encoding the core TRAPPC6 protein have been reported in humans called *TRAPPC6A* and  
2 *TRAPPC6B*<sup>11</sup>. *D.melanogaster* and *S.cerevisiae* have a single gene encoding this subunit, *Trs33*.  
3 It has been assumed that TRAPPC6A and TRAPPC6B could incorporate into either TRAPP II or  
4 TRAPP III complex, as both proteins are capable of forming a heterodimer in complex with  
5 TRAPPC3 *in vitro*<sup>11-13</sup>.

6 A homozygous nonsense variant in *TRAPPC6B* was recently described in an Iranian  
7 family in association with intellectual disability<sup>14</sup> and a homozygous splice-site founder  
8 mutation was found in three Egyptian families in association with microcephaly, intellectual  
9 disability, autism, epilepsy, dystonia and reduced brain volume<sup>15</sup>. A fifth family was then  
10 reported<sup>16</sup>. In this report, we describe 29 individuals from 18 unrelated families with biallelic  
11 variants in *TRAPPC6B* manifesting microcephaly, epilepsy, and intellectual disability with  
12 phenotypic expansion to include spasticity. We examine variant impact on TRAPPC6B and  
13 TRAPP II- versus TRAPP III-specific protein levels, anterograde protein trafficking, and Golgi  
14 apparatus morphology in patient fibroblasts. Finally, we tested whether *TRAPPC6B* can regulate  
15 neuromotor function using *Drosophila* locomotor and wing posture assays. Together, the  
16 findings expand the *TRAPPC6B*-associated clinical and neuroradiologic phenotype and  
17 demonstrate patient variants disrupt TRAPPC6B and TRAPP II protein levels, trafficking, and  
18 Golgi morphology. We further find that TRAPPC6B preferentially associates with TRAPP II  
19 complex members, which support the observation that TRAPPC6B clinical phenotypes more  
20 closely align with TRAPP II complex disorders.

21

## 22 **Materials and methods**

23 **Patient recruitment, sequencing and variant calling:** All human subject studies were  
24 performed in accordance with the ethical standards of the responsible committee on human  
25 experimentation according to institutional and national standards. Proper informed consent was  
26 obtained for all participants. Clinical phenotypes (**Supplementary Clinical Summaries**) were  
27 abstracted from written records, supplemented by review of available neuroimaging, facial  
28 photographs, and laboratory and clinical electrophysiologic data. Patient videos were reviewed  
29 by pediatric movement disorder neurologists (J.H. and M.C.K.). Phenograms were created using

1 R (4.1.0). Patients with data not available for a category were not included in that category's  
 2 calculations. TRAPP disease gene summary was created from OMIM.org, accessed August  
 3 2022. Sequencing details and filtering criteria used for each case are provided in the  
 4 **Supplementary Methods**.

5 **MRI analysis, processing and volumetric quantification:** Neuroimaging findings were  
 6 reviewed and summarized by a board-certified neuroradiologist (P.C.). Several image processing  
 7 steps were then performed on the T1-weighted brain MRIs<sup>17</sup>, including registration to the Colin  
 8 27 Average Brain Atlas, correcting image bias using the N4 algorithm, followed by intensity  
 9 normalisation and image de-noising, using anisotropic diffusion. Skull stripping was performed  
 10 using an in-house algorithm developed in Python. In this approach, intradural CSF was identified  
 11 using thresholding and morphological operations, following which the lateral ventricles were  
 12 isolated based on their spatial location, allowing the volume of the lateral ventricles (in mL) to  
 13 be extracted. Cerebral brain tissues (grey matter, white matter) were then isolated based on their  
 14 MR intensities using the Expectation Maximization (EM)/Markov Random Field (MRF)  
 15 approach. From the cortical grey matter segmentation, three measures of cortical shape were  
 16 performed (cortical thickness, curvature and sulcal depth) to quantify shape abnormalities.  
 17 Measures were converted to a z-score from healthy cortical shape measures measured from the  
 18 corresponding cortical region compared to the Child Mind Institute Healthy Brain Network  
 19 cohort of 564 typically developing children (TDC) (Equation 1), based on cortical regions from  
 20 the Automated Anatomical Labelling (AAL) atlas.

$$21 \quad (\text{Eqn 1}) \quad z\text{-score}_{subject} = \frac{(x_{subject} - \mu_{TDC})}{\sigma_{TDC}}$$

22 **MRI statistical analysis:** Six participants passed the quality checks for initial MRI data quality  
 23 and processed segmentations (Families 3,4,6,10). For each participant, z-scores of grey matter  
 24 volume, white matter volume, ventricle asymmetry (Equation 2), were extracted.

$$26 \quad (\text{Eqn 2}) \quad \text{Ventricle asymmetry} = \frac{(vol_{left} - vol_{right})}{(vol_{left} + vol_{right})}$$



1 **Yeast Two Hybrid Assay:** *TRAPP* open reading frames were cloned into pGADT7 and  
2 pGBKT7 plasmids (Clontech, USA). Standard yeast methods were used for transformation of the  
3 pGADT7 and pGBKT7 constructs into AH109 and Y187 yeast strains, respectively. Diploid  
4 cells were produced by mating on solid YPD media and then selected for on solid synthetic  
5 complete (SC) media lacking leucine and tryptophan (DDO). Single colonies of each diploid  
6 were then cultured in liquid DDO and then spotted on either DDO or on SC media lacking  
7 leucine, tryptophan and histidine (TDO) to assess for interactions. Plates were grown at 30°C for  
8 72 hours.

9 **Membrane Trafficking Assay:** The retention using selective hooks (RUSH) assay was  
10 performed as described in Boncompain et al., 2012. Briefly, fibroblasts grown in Dulbecco's  
11 modified eagle medium (DMEM) supplemented with 10% fetal bovine serum were transfected  
12 by electroporation with the Golgi-resident enzyme sialyl transferase-GFP (ST-GFP) fused to  
13 streptavidin binding protein. The plasmid also expressed KDEL-tagged streptavidin for  
14 endoplasmic reticulum (ER) retention. For the rescue experiments, fibroblasts were co-  
15 transfected with ST-GFP and TRAPPC6B-RFP. 24 hours after transfection, biotin was added to  
16 a final concentration of 60 µM to release the reporter from the ER hook. Live cells were imaged  
17 by fluorescence microscopy every 2 minutes for 60 minutes using a Nikon Livescan sweptfield  
18 confocal microscope with a 40X objective lens (NA 0.95). Integrated fluorescence intensity at  
19 the Golgi region and from whole cell was measured every 2 minutes using ImageJ v1.53. The  
20 ratio between fluorescent intensities within the Golgi and whole cell was generated for each time  
21 point. The first time point corresponding to background was subtracted from all time points.  
22 These values were then plotted as the mean percentage of maximal intensity.

23 **Golgi Morphology:** Fibroblasts were cultured in DMEM supplemented with 10% fetal bovine  
24 serum. The cells were washed 2 times with phosphate buffered saline solution (PBS) then fixed  
25 with 4% paraformaldehyde (PFA) for 15 minutes at room temperature, quenched with 0.1 M  
26 glycine for 10 minutes and permeabilized with 0.1% Triton X-100 for 7 minutes. Blocking was  
27 performed in 5% normal goat serum in PBS for 45 minutes at room temperature. Primary  
28 antibodies were prepared in 5% normal goat serum and were added to the cells and incubated  
29 overnight at 4°C. Cells were washed 2 times for 5 minutes each with PBS. Secondary antibodies  
30 were diluted in 5% normal goat serum in PBS and incubated with the cells at room temperature

1 for one hour and then removed. Hoechst 33342 (Thermo Fisher Scientific) was diluted in PBS  
2 (1:2000) and added to stain the nucleus for 2 minutes followed by 2 washes with PBS wash for  
3 10 minutes each. The coverslips were then mounted with Prolong Gold Anti Fade. Images were  
4 acquired on an Olympus FV10i confocal laser scanning microscope fitted with a 60X objective,  
5 NA 1.35. The number of Golgi fragments per cell were quantified using Imaris software c.9.8.0  
6 (Bitplane, Concord, MA). Golgi structures were identified from the mannosidase II channel  
7 using the following surface parameters; surface details = 0.22 $\mu$ m and thresholding with a  
8 background subtraction of the depicted Golgi spherical structures that have diameter smaller than  
9 0.55  $\mu$ m in size. Statistical analyses were carried out using one-way ANOVA corrected for  
10 Tukey's multiple comparisons using GraphPad Prism 6.01. A p-value of 0.05 was considered to  
11 be statistically significant.

12 **Immunoblotting:** Fibroblasts were washed twice with PBS and lysed in a solution containing  
13 50mM Tris pH 7.2, 150 mM NaCl, 0.5 mM EDTA, 1 mM DTT, 1% Triton X-100 and protease  
14 inhibitor cocktail (EDTA-free; Roche). The lysate was clarified at 13000 $\times$ g for 30 minutes at  
15 4°C. A total of 30-40  $\mu$ g of whole cell lysate was loaded and fractionated in either 8% or 15%  
16 SDS-polyacrylamide gels (SDS-PAGE). The gels were transferred to nitrocellulose membranes  
17 and blocked with 5% skim milk powder in PBS with 0.1% Tween (PBS-T) for 1 hour. Primary  
18 antibodies were incubated in PBS-T overnight at 4°C, washed 3 times with PBS-T for 5 minutes  
19 each, and secondary antibodies were incubated for 1 hour at room temperature. Membranes were  
20 then washed 3 times with PBS-T for 5 minutes each and incubated with Pierce ECL western blot  
21 substrate (Thermo Fisher Scientific) and detected using an Amersham Imager 600 (GE  
22 Healthcare).

23 **Immunoprecipitation:** HeLa cells were seeded in 10cm dishes 24 hours prior to co-transfecting  
24 cells with 5 $\mu$ g of DNA expressing either TRAPPC6A-V5/TRAPPC10-FLAG, TRAPPC6A-  
25 V5/TRAPPC11-FLAG, TRAPPC6B-V5/TRAPPC10-FLAG, or TRAPPC6B-V5/TRAPPC11-  
26 FLAG using Jet Prime (Polyplus). 48 hours after transfection cells were washed twice with ice  
27 cold PBS and lysed in a solution containing 50mM Tris pH 7.2, 150 mM NaCl, 0.5 mM EDTA,  
28 1 mM DTT, 1% Triton X-100 and protease inhibitor cocktail (EDTA-free; Roche). The lysate  
29 was clarified at 13000 $\times$ g for 30 minutes at 4°C. A total of 500 $\mu$ g of lysate was incubated with  
30 20 $\mu$ l (10 $\mu$ l bead volume) anti-Flag M2 affinity beads (Sigma Aldrich) in IP-buffer (50mM Tris

1 pH 7.2, 150 mM NaCl, 0.5 mM EDTA, 0.1% Triton X-100 and protease inhibitor cocktail) for 3  
2 hours at 4°C on an orbital shaker. The beads were collected by centrifugation at 5000 rpm for 30  
3 seconds at 4°C and washed 2 times with IP-buffer and 2 times with IP-buffer without Triton X-  
4 100. The beads were resuspended in 20µL of 2×Laemmli sample buffer containing β-  
5 mercaptoethanol and heated at 95°C for 5 minutes to dissociate the immune complexes. The  
6 beads were pelleted by centrifugation and SDS-PAGE for protein from input (whole-cell  
7 extracts) and immunoprecipitated proteins was performed as described above.

8 **Molecular Biology Techniques:** Standard molecular biological techniques were used to  
9 generate FLAG-tagged, RFP-tagged and V5 tagged constructs. TRAPPC6B variants were  
10 generated by site-directed mutagenesis.

11 **Antibodies:** Antibodies used in this study were: anti-TRAPPC2L (1:1000 mouse monoclonal,  
12 Santa Cruz sc-377322), anti-TRAPPC3 (1:1000 rabbit polyclonal,<sup>18</sup>), anti-TRAPPC6A (1:500  
13 mouse monoclonal, Santa Cruz sc-376032), anti-TRAPPC6B (1:1000 rabbit polyclonal,  
14 ABclonal A15561), anti-TRAPPC8 (1:1000 rabbit polyclonal, Abcam ab122692), anti-  
15 TRAPPC9 (1:2000 rabbit polyclonal, LS Bio LS-C750497), anti-TRAPPC10 (1:500 mouse  
16 monoclonal, Santa Cruz sc-101259), anti-TRAPPC12 (1:1000 rabbit polyclonal,<sup>18</sup>), anti-FLAG  
17 (1:5000 mouse monoclonal, Sigma F1804), anti-α-Tubulin (1:5000 mouse monoclonal, Sigma  
18 T6199), anti-RFP (1:500 mouse monoclonal, Rockland 200-301-379S), anti-mannosidase II  
19 (1:200 kind gift from Dr Kelley Moreman), anti V5 (1:1000 rabbit monoclonal, Cell Signaling  
20 13202).

21 **Fly rearing and genetics:** *Drosophila* were reared on a standard cornmeal, yeast, sucrose food  
22 from the BIO5 media facility, University of Arizona. Stocks for experiments were reared at  
23 25°C, 60-80% relative humidity with 12:12 light/dark cycle. Crosses for controls and mutants  
24 and animals selected for locomotor assay were maintained at an elevated temperature of 28.5°C.  
25 Fly stocks were obtained from the Bloomington *Drosophila* Stock Center (NIH P40OD018537).  
26 Crosses were performed with *w<sup>1118</sup>* for heterozygous studies of genetic controls.  
27 P[TRiP.HMJ21139]attP40 was used for expression of UAS-Trs33-RNAi<sup>19</sup>. Pan-neuronal Gal-4  
28 driver (ELAV, CG4262) was used to direct RNAi expression to post-mitotic neurons during  
29 development and throughout adulthood.

1 **Locomotor assays:** Naïve, unmated flies collected as pharate adults and controlled for humidity,  
2 temperature, and time of day (30% RH, 24°C, 0900-1100) were used. Flies at 14 days post-  
3 eclosion were adapted to room conditions for 1 hour before assaying in groups of 3-20 in coded  
4 vials by blinded experimenters <sup>20</sup>. Distance was determined from still images from video at 3  
5 seconds post-tapping using ImageJ measured distance function from the middle of the fly to the  
6 bottom of the vial and averaged between flies for each trial. Graphs and t-test statistic  
7 calculations were performed in R (4.1.0). For box and whisker plots, box indicates 75<sup>th</sup> and 25<sup>th</sup>  
8 percentile with median line; whiskers indicate range of data.

9 **Erect wing scoring:** Each video was manually assessed for flies with erect wing phenotype  
10 defined as wings held upright and away from the body <sup>21</sup>. The wing must have been held erect  
11 during the majority of the video, and upright wing postures limited to before flight or during  
12 grooming were excluded. Statistics were determined both as a 3-way and pairwise against both  
13 control genotypes using Chi-squared analysis in R (4.1.0).

14

## 15 **Results**

16 Through Genematcher, we identified 18 families with biallelic variants in *TRAPPC6B*  
17 from international collaborators. In our cohort, 27/29 individuals segregated loss of function  
18 (LoF) (nonsense and splice-site) homozygous variants, with one individual carrying compound  
19 heterozygous splice-site/missense variants and one individual carrying homozygous missense  
20 variants. The M:F ratio was 1.6:1 and average age of diagnosis was 7.5 years (range 14 months  
21 to 35 years). Affected families were from 11 countries (Iran, Morocco, Pakistan, Tunisia, France,  
22 Mali, Gambia, Egypt, Saudi Arabia, Turkey, India) and frequently included multiple affected  
23 individuals (**Supplementary Fig. 1**). Homozygous variants including 7 homozygous nonsense  
24 (n= 12 individuals), 8 canonical splice-site variants (n=17 individuals), and 1 missense variant  
25 (n=1 individuals) were identified using whole exome sequencing (WES). Variant information is  
26 provided in **Supplementary Table 1**. Additional sequencing information is provided in  
27 **Supplementary Methods**.

1 We conducted detailed clinical and neuroradiologic assessments. Frequency of clinical  
2 features are summarized in **Table 2** and **Fig. 1A** with full descriptions in the **Supplementary**  
3 **Clinical Summaries**. We noted a constellation of cognitive and motor features partially  
4 overlapping a prior report of individuals with *TRAPPC6B* variants (Marin-Valencia et al., 2018).  
5 Consistent with prior reports, we found complex neurodevelopmental features including  
6 intellectual disability, expressive language defects, autism, seizures or epilepsy, and  
7 neurobehavioral features such as aggression and self-injury in some patients (**Fig. 1A**). Many  
8 patients also exhibited difficulty with walking and some also had issues sitting. Stereotyped  
9 movements were evident in most individuals, with dystonia, spasticity, and contractures, at lower  
10 frequency. On examination, knee-jerk reflexes were often increased, although they were absent  
11 in one patient. Reduced muscle bulk was occasionally observed in the most impaired patients  
12 (GMFCS 4-5). Microcephaly was a notable feature in this cohort, with some patients as severe as  
13  $<-6.5$  SD. This microcephaly does not appear to be progressive based on serial clinical  
14 assessments. Dysmorphic features include a variety of inconsistent facial features, tapered  
15 fingers, and arachnodactyly (**Fig. 1B-N**). MRI was assessed for 16 individuals (**Fig. 2**) and  
16 identified reductions in cortex and cerebellum with increased ventricle size. Foreshortening or  
17 thinning of corpus callosum and white matter increased intensity or volume loss were consistent  
18 imaging features. Volumetric measures of MRI compared to age-matched large populations<sup>17</sup>  
19 did not identify a specific region driving the observed microcephaly (**Fig. 2N**). Of note, the  
20 individuals with missense variants (patients 7 and 29) exhibited similar phenotypes, suggesting  
21 that missense variants could potentially impair protein function and disrupt nervous system  
22 development.

### 23 **TRAPPC6B p.Q152\* impairs TRAPPC3 binding and diminishes protein expression for** 24 **TRAPPC6B and TRAPP II complex members**

25 Given that our previous work suggested that the carboxy-terminus of TRAPPC6A  
26 interacts with adaptor subunit TRAPPC2L and both TRAPPC6A and TRAPPC6B interact with  
27 TRAPPC2L and TRAPPC3<sup>22</sup>, we examined interactions between TRAPPC6B and both  
28 TRAPPC2L and TRAPPC3. While an interaction between both TRAPPC2L and TRAPPC3 was  
29 seen for the wild type TRAPPC6B irrespective of the vectors used, only the TRAPPC3

1 interaction was affected by the p.Q152\* allele from affected individuals in family 15 (**Fig. 3A**  
2 **and 3B**).

3 This result suggests that the carboxy-terminus of TRAPPC6B is important for its  
4 interaction with TRAPPC3 and that this interaction is diminished in TRAPPC6B p.Q152\*. Since  
5 the TRAPPC3-TRAPPC6B heterodimer is important for the assembly of the TRAPP complexes,  
6 it is not unreasonable to expect that TRAPPC6B variants will decrease the presence of subunits  
7 that rely on this heterodimer to associate with TRAPP complexes. Indeed, in p.Q152\*  
8 fibroblasts, several TRAPP protein levels were decreased, with the strongest effect seen for the  
9 two TRAPP II-specific proteins TRAPPC10 and TRAPPC9 (**Fig. 3C**). There was a near  
10 complete absence of detectable amounts of TRAPPC6B, suggesting potential nonsense mediated  
11 decay or truncated protein instability (**Fig. 3C**). It is noteworthy that we consistently saw an  
12 increase in the levels of TRAPPC6A in the fibroblasts from the affected individuals, perhaps  
13 representing an attempted compensatory response.

#### 14 **TRAPP II complex members associate preferentially with TRAPPC6B**

15 We next examined whether TRAPPC6B was preferentially associated with TRAPP II  
16 complexes. To perform this experiment, HeLa cells were mock transfected or co-transfected with  
17 TRAPPC6A-V5/TRAPPC10-FLAG, TRAPPC6A-V5/TRAPPC11-FLAG, TRAPPC6B-  
18 V5/TRAPPC10-FLAG, or TRAPPC6B-V5/TRAPPC11 and associated proteins were collected  
19 on beads harboring anti-FLAG IgG and probed for V5 and FLAG. TRAPPC11 transfections  
20 target TRAPP III while the TRAPPC10 transfections target TRAPP II.

21 Unlike TRAPPC6A, which equally co-precipitated with TRAPPC10 and TRAPPC11,  
22 TRAPPC6B was significantly more enriched with TRAPPC10 compared to TRAPPC11 (**Fig. 4A**  
23 **and 4B**). These results suggest that TRAPP II complexes are enriched in TRAPPC6B compared  
24 to TRAPP III.

#### 25 **Patient-derived fibroblasts have ER-Golgi trafficking defects and altered Golgi** 26 **morphology**

1 Previous studies have shown an anterograde trafficking defect for variants in most  
2 TRAPP-associated genes<sup>8,22-24</sup>. Therefore, we subjected fibroblasts derived from families 4  
3 (c.149+2 T>A splice-site; patients 5 and 6) and 15 (p.Q152\*; patients 23 and 24) to a membrane  
4 trafficking assay<sup>25</sup>. In all four cases, upon biotin-mediated release of an ER-retained protein  
5 there was a delay in transport to the Golgi compared to control (**Fig. 5A and 5B**). This was  
6 determined to be TRAPPC6B-related since transfection of RFP-tagged TRAPPC6B resulted in a  
7 noticeable rescue of this trafficking defect. Golgi fragmentation is also commonly seen in cells  
8 harboring TRAPP gene mutations as well as in cells with mutations in other membrane  
9 trafficking-related proteins<sup>26</sup>. When the fibroblasts from affected individuals were compared to  
10 control, a significant increase in Golgi fragmentation was seen (**Fig. 5C and 5D**). This increase  
11 was rescued to near wild type levels by transfection of wild type TRAPPC6B. Together, our  
12 functional studies suggest that variants in TRAPPC6B can disrupt ER to Golgi protein  
13 trafficking and lead to altered Golgi morphology.

#### 14 **Loss of neuronal TRAPPC6B impairs locomotion and wing posture in *Drosophila***

15 We examined whether TRAPPC6B could regulate neuromotor function in a *Drosophila*  
16 model. The *Drosophila* ortholog, Trs33, has excellent conservation with TRAPPC6B (DIOPT  
17 score=15/15) with 72% similarity and 54% identity (flyrnai.org). As Trs33 is an essential gene  
18 for development, we utilized an RNAi knockdown approach specifically in neurons under the  
19 ELAV-Gal4 driver. Neuronal expression of Trs33 shRNA decreased distance traveled in a  
20 locomotor assay compared to the heterozygous controls of the Gal4 and UAS lines alone (**Fig.**  
21 **6A**). Additionally, an abnormality of wing posture was noted in 10.6% of these animals,  
22 suggesting defects in the innervation of the indirect flight muscles (**Fig. 6B**). Together, this  
23 suggests TRAPPC6B is crucial for motor function.

## 24 **Discussion**

25 Marin-Valencia et al. recently reported a founder *TRAPPC6B* homozygous splice-site  
26 variant segregating with disease in 3 Egyptian families and found that morpholino treatment  
27 against *Danio* TrappC6B led to reduced head size and increased spontaneous neuronal activity in  
28 zebrafish. We present here 29 individuals from 18 families with biallelic variants in *TRAPPC6B*.  
29 These individuals share a syndromic phenotype consisting of primary microcephaly, global

1 developmental delay/intellectual disability, stereotypies and impaired expressive language. Brain  
2 MRI findings include volume loss, thin corpus callosum, and white matter signal abnormalities.  
3 Variable features include epilepsy, spasticity/dystonia, and dysmorphic features. Our findings  
4 thus provide an independent validation for biallelic *TRAPPC6B* variants as a cause of a complex  
5 neurodevelopmental disorder and expand on the clinical features.

6 Notably, two individuals in our series harbored *TRAPPC6B* variants of unknown  
7 significance (patients 7 and 29). The individual with compound heterozygous splice and small  
8 deletion variants (patient 7) had a milder phenotype, gaining the ability to use limited expressive  
9 language, falling short of a formal diagnosis of microcephaly, and achieving independent  
10 walking by age 3. The homozygous missense variant (p.G124V) has a CADD score of 32, is  
11 absent from gnomAD, and classified as a VOUS in Varsome. This individual (patient 29) has  
12 clinical features that match the remaining cohort, including microcephaly, spasticity, epilepsy,  
13 and a thin corpus callosum. However, we were not able to conduct functional studies on this  
14 variant. This suggests that missense variants can contribute to a *TRAPPC6B* genetic disorder,  
15 with similar but potentially milder manifestations, but further studies are needed. The remaining  
16 27 individuals in the present cohort and those reported by Marin-Valencia all had homozygous  
17 splice-site and early stop variants. We confirmed diminished protein expression in a family with  
18 a homozygous early stop variant (p.Q152\*), consistent with a loss of function variant that may  
19 manifest with decreased protein abundance or the loss of an as-yet unidentified motif in the  
20 carboxy-terminus important for subcellular localization or protein-protein interactions. One  
21 limitation of this work is the fact that we only tested the effect of this particular variant on  
22 *TRAPPC6B* levels.

23 Our biochemical studies suggest that variants in *TRAPPC6B* such as p.Q152\* likely  
24 impair TRAPP II complex stability by a weakened interaction with *TRAPPC3* and decreasing  
25 protein expression for *TRAPPC6B* and TRAPP II complex members. *TRAPPC6B* appears to  
26 preferentially associate with TRAPP II compared to TRAPP III. It is interesting that *TRAPPC6A*  
27 levels increase in the absence of *TRAPPC6B* as seen in affected individuals of family 15. It is  
28 possible that *TRAPPC6A* can partially compensate for the loss of *TRAPPC6B*. This would be  
29 consistent with the studies of TRAPP guanine nucleotide exchange factor (GEF) activity towards  
30 Rab for recombinant *Drosophila* and human complexes<sup>3,27</sup>. In *Drosophila*, only a single



1 (TRAPPC6B) homologue is found, while humans have both TRAPPC6A and TRAPPC6B.  
2 Therefore, *Drosophila* TRAPP complexes do not distinguish between the two TRAPPC6 human  
3 orthologues and TRAPP III is functional with TRAPPC6B. In the human recombinant  
4 complexes, TRAPPC6A was used for assembling both TRAPP II and III, and both complexes  
5 were functional<sup>3,27</sup>. It remains possible that had TRAPPC6B been used in the recombinant  
6 TRAPP II complex, stronger or additional GEF activity would have been seen. Nevertheless, our  
7 present study suggests a bias for TRAPPC6B in TRAPP II and implies the cell has a mechanism  
8 to distinguish and incorporate specific TRAPPC6 orthologues into specific TRAPP complexes. It  
9 is presently unclear how this would be accomplished.

10 Disruption of TRAPP II stability has been shown previously to affect anterograde  
11 trafficking (Rawlins et al., 2022). Biallelic variants of *TRAPPC6B* show similar cellular features,  
12 such as an ER- to -Golgi trafficking defect and altered Golgi morphology.

13 We found that neuronal loss of TRAPPC6B in a *Drosophila* model impaired locomotion  
14 and wing posture. The erect wing phenotype has been linked to impaired synaptic growth<sup>28</sup> and  
15 disrupted central nervous system commissures and longitudinal tracts innervating the indirect  
16 flight muscles which regulate wing posture<sup>29</sup>. Knocking down Trs33 in *Drosophila* with the  
17 Mef2 muscle and neuron expressing Gal4-driver was reported to impair flight ability, but without  
18 obvious changes to the flight muscles, myofibrils, or sarcomeres themselves<sup>30</sup>. Together with  
19 our ELAV-mediated neuronal knockdown, this suggests a neuronal origin for the previously  
20 reported flight muscle weakness that has similarities to the postural/locomotor impairments in  
21 *TRAPPC6B*-affected individuals.

22 *TRAPPC6B*-associated phenotypes overlap substantially with variants in genes encoding  
23 other TRAPP subunits. These phenotypes include intellectual disability, movement disorders,  
24 white matter involvement, cerebellar volume loss, microcephaly, and muscle involvement  
25 (**Table 1**)<sup>8</sup>. Many TRAPP-related disorders, particularly those affecting TRAPP III, identified a  
26 progressive loss of cerebral volume over time (**Table 1**). However, we did not find evidence that  
27 loss of *TRAPPC6B* function causes neurodegeneration. Treating clinicians did not note  
28 progressive microcephaly and available OFC measurements seem to start low at birth and  
29 maintain the same course. Consistent with the biochemical studies, we found *TRAPPC6B*

1 phenotypes overlapped more closely for genes exclusively localized to TRAPP II (*TRAPPC9*  
2 (#613192) and *TRAPPC10* (\*602103)). In contrast, individuals with variants in genes  
3 exclusively encoding autophagy-associated TRAPP III components (*TRAPPC11* and  
4 *TRAPPC12*) are notably different from the *TRAPPC6B* patients. *TRAPPC11* variants lead to a  
5 complex neurodevelopmental disorder with muscular dystrophy and visual system impairments  
6 and individuals with *TRAPPC12* display a progressive encephalopathy. This supports the  
7 conclusion that *TRAPPC6B* is important for TRAPP II complex function with impairments  
8 resulting in a distinct and recognizable TRAPPopathy. A major challenge in understanding the  
9 neurological disorder linked to TRAPP II variants is the consequence of trafficking defects on  
10 neuronal function. We identified a potential defect in neuronal innervation in the fly model,  
11 however we were unable to investigate further due to the lack of human neuronal cells. Cellular  
12 reprogramming of patient fibroblasts into patient-derived induced pluripotent stem cells (iPSCs)  
13 that can be induced to differentiate into specific neuronal cells can overcome this limitation and  
14 provide better insight into the etiology of NDDs associated with TRAPP II variants.

15

## 16 **Data availability**

17 The authors confirm that the data supporting the findings of this study are available within the  
18 article and/or its supplementary material. Additional raw and/or de-identified data supporting the  
19 findings of this study are available from the corresponding authors upon reasonable request.

20

## 21 **Acknowledgements**

22 We are grateful to the patients and their families for involvement in these studies. We  
23 acknowledge Dr. Hossein Mozdhehpanah and Dr. Paulien A. Terhal for providing patient  
24 clinical information. We appreciate the assistance of Dr. Bob Argiropoulos and Nadine Gamache  
25 with fibroblast cultures.

26

## 27 **Funding**

1 Portions of this work were supported by a Cerebral Palsy Alliance Research Foundation Career  
2 Development Award to SB, and by the U.S. National Institutes of Health (1R01NS106298 and  
3 1R01NS127108 to MCK).

4

## 5 **Competing interests**

6 The authors have no competing interests to report that could influence the conclusions of this  
7 manuscript.

8

## 9 **Supplementary material**

10 Supplementary material is available at *Brain* online.

11

## 12 **References**

13

- 14 1. Chin HF, Cai Y, Menon S, Ferro-Novick S, Reinisch KM, De La Cruz EM. Kinetic  
15 analysis of the guanine nucleotide exchange activity of TRAPP, a multimeric Ypt1p exchange  
16 factor. *J Mol Biol.* Jun 5 2009;389(2):275-88. doi:10.1016/j.jmb.2009.03.068
- 17 2. Riedel F, Galindo A, Muschalik N, Munro S. The two TRAPP complexes of metazoans  
18 have distinct roles and act on different Rab GTPases. *J Cell Biol.* Feb 5 2018;217(2):601-617.  
19 doi:10.1083/jcb.201705068
- 20 3. Jenkins ML, Harris NJ, Dalwadi U, *et al.* The substrate specificity of the human  
21 TRAPPII complex's Rab-guanine nucleotide exchange factor activity. *Commun Biol.* Dec 4  
22 2020;3(1):735. doi:10.1038/s42003-020-01459-2
- 23 4. Knödler A, Feng S, Zhang J, *et al.* Coordination of Rab8 and Rab11 in primary  
24 ciliogenesis. *Proc Natl Acad Sci U S A.* Apr 6 2010;107(14):6346-51.  
25 doi:10.1073/pnas.1002401107

- 1 5. Westlake CJ, Baye LM, Nachury MV, *et al.* Primary cilia membrane assembly is initiated  
2 by Rab11 and transport protein particle II (TRAPP II) complex-dependent trafficking of Rabin8  
3 to the centrosome. *Proc Natl Acad Sci U S A.* Feb 15 2011;108(7):2759-64.  
4 doi:10.1073/pnas.1018823108
- 5 6. Scrivens PJ, Noueihed B, Shahrzad N, Hul S, Brunet S, Sacher M. C4orf41 and TTC-15  
6 are mammalian TRAPP components with a role at an early stage in ER-to-Golgi trafficking. *Mol*  
7 *Biol Cell.* Jun 15 2011;22(12):2083-93. doi:10.1091/mbc.E10-11-0873
- 8 7. Stanga D, Zhao Q, Milev MP, Saint-Dic D, Jimenez-Mallebrera C, Sacher M.  
9 TRAPPC11 functions in autophagy by recruiting ATG2B-WIPI4/WDR45 to preautophagosomal  
10 membranes. *Traffic.* May 2019;20(5):325-345. doi:10.1111/tra.12640
- 11 8. Sacher M, Shahrzad N, Kamel H, Milev MP. TRAPPopathies: An emerging set of  
12 disorders linked to variations in the genes encoding transport protein particle (TRAPP)-  
13 associated proteins. *Traffic.* Jan 2019;20(1):5-26. doi:10.1111/tra.12615
- 14 9. Bassik MC, Kampmann M, Lebbink RJ, *et al.* A systematic mammalian genetic  
15 interaction map reveals pathways underlying ricin susceptibility. *Cell.* Feb 14 2013;152(4):909-  
16 22. doi:10.1016/j.cell.2013.01.030
- 17 10. Scrivens PJ, Shahrzad N, Moores A, Morin A, Brunet S, Sacher M. TRAPPC2L is a  
18 novel, highly conserved TRAPP-interacting protein. *Traffic.* Jun 2009;10(6):724-36.  
19 doi:10.1111/j.1600-0854.2009.00906.x
- 20 11. Kümmel D, Müller JJ, Roske Y, Henke N, Heinemann U. Structure of the Bet3-Tpc6B  
21 core of TRAPP: two Tpc6 paralogs form trimeric complexes with Bet3 and Mum2. *J Mol Biol.*  
22 Aug 4 2006;361(1):22-32. doi:10.1016/j.jmb.2006.06.012
- 23 12. Tokarev AA, Taussig D, Sundaram G, *et al.* TRAPP II complex assembly requires Trs33  
24 or Trs65. *Traffic.* Dec 2009;10(12):1831-44. doi:10.1111/j.1600-0854.2009.00988.x
- 25 13. Kümmel D, Oeckinghaus A, Wang C, Krappmann D, Heinemann U. Distinct  
26 isocomplexes of the TRAPP trafficking factor coexist inside human cells. *FEBS Lett.* Nov 12  
27 2008;582(27):3729-33. doi:10.1016/j.febslet.2008.09.056

- 1 14. Harripaul R, Vasli N, Mikhailov A, *et al.* Mapping autosomal recessive intellectual  
2 disability: combined microarray and exome sequencing identifies 26 novel candidate genes in  
3 192 consanguineous families. *Mol Psychiatry*. Apr 2018;23(4):973-984. doi:10.1038/mp.2017.60
- 4 15. Marin-Valencia I, Novarino G, Johansen A, *et al.* A homozygous founder mutation in  
5 TRAPPC6B associates with a neurodevelopmental disorder characterised by microcephaly,  
6 epilepsy and autistic features. *J Med Genet*. Jan 2018;55(1):48-54. doi:10.1136/jmedgenet-2017-  
7 104627
- 8 16. Nair P, El-Bazzal L, Mansour H, *et al.* Further Delineation of the TRAPPC6B Disorder:  
9 Report on a New Family and Review. *J Pediatr Genet*. Dec 2019;8(4):252-256. doi:10.1055/s-  
10 0039-1693664
- 11 17. Pagnozzi AM, Dowson N, Doecke J, *et al.* Identifying relevant biomarkers of brain injury  
12 from structural MRI: Validation using automated approaches in children with unilateral cerebral  
13 palsy. *PLoS One*. 2017;12(8):e0181605. doi:10.1371/journal.pone.0181605
- 14 18. Milev MP, Hasaj B, Saint-Dic D, Snounou S, Zhao Q, Sacher M. TRAMM/TrappC12  
15 plays a role in chromosome congression, kinetochore stability, and CENP-E recruitment. *J Cell*  
16 *Biol*. Apr 27 2015;209(2):221-34. doi:10.1083/jcb.201501090
- 17 19. Ke H, Feng Z, Liu M, *et al.* Collagen secretion screening in *Drosophila* supports a  
18 common secretory machinery and multiple Rab requirements. *J Genet Genomics*. Jun 1  
19 2018;doi:10.1016/j.jgg.2018.05.002
- 20 20. Kim M, Sandford E, Gatica D, *et al.* Mutation in ATG5 reduces autophagy and leads to  
21 ataxia with developmental delay. *eLife*. Jan 2016;5:e12245.
- 22 21. Fernandes C, Rao Y. Genome-wide screen for modifiers of Parkinson's disease genes in  
23 *Drosophila*. *Mol Brain*. Apr 19 2011;4:17. doi:10.1186/1756-6606-4-17
- 24 22. Al-Deri N, Okur V, Ahimaz P, *et al.* A novel homozygous variant in TRAPPC2L results  
25 in a neurodevelopmental disorder and disrupts TRAPP complex function. *J Med Genet*. Sep  
26 2021;58(9):592-601. doi:10.1136/jmedgenet-2020-107016
- 27 23. Van Bergen NJ, Guo Y, Al-Deri N, *et al.* Deficiencies in vesicular transport mediated by  
28 TRAPPC4 are associated with severe syndromic intellectual disability. *Brain*. Jan 1  
29 2020;143(1):112-130. doi:10.1093/brain/awz374

- 1 24. Rawlins LE, Almousa H, Khan S, *et al.* Biallelic variants in TRAPPC10 cause a  
2 microcephalic TRAPPopathy disorder in humans and mice. *PLoS Genet.* Mar  
3 2022;18(3):e1010114. doi:10.1371/journal.pgen.1010114
- 4 25. Boncompain G, Divoux S, Gareil N, *et al.* Synchronization of secretory protein traffic in  
5 populations of cells. *Nat Methods.* Mar 11 2012;9(5):493-8. doi:10.1038/nmeth.1928
- 6 26. Makhoul C, Gosavi P, Gleeson PA. Golgi Dynamics: The Morphology of the  
7 Mammalian Golgi Apparatus in Health and Disease. *Front Cell Dev Biol.* 2019;7:112.  
8 doi:10.3389/fcell.2019.00112
- 9 27. Harris NJ, Jenkins ML, Dalwadi U, *et al.* Biochemical Insight into Novel Rab-GEF  
10 Activity of the Mammalian TRAPPIII Complex. *J Mol Biol.* Sep 3 2021;433(18):167145.  
11 doi:10.1016/j.jmb.2021.167145
- 12 28. Haussmann IU, White K, Soller M. Erect wing regulates synaptic growth in *Drosophila*  
13 by integration of multiple signaling pathways. *Genome Biol.* Apr 17 2008;9(4):R73.  
14 doi:10.1186/gb-2008-9-4-r73
- 15 29. DeSimone S, Coelho C, Roy S, VijayRaghavan K, White K. ERECT WING, the  
16 *Drosophila* member of a family of DNA binding proteins is required in imaginal myoblasts for  
17 flight muscle development. *Development.* Jan 1996;122(1):31-9. doi:10.1242/dev.122.1.31
- 18 30. Schnorrer F, Schönbauer C, Langer CC, *et al.* Systematic genetic analysis of muscle  
19 morphogenesis and function in *Drosophila*. *Nature.* Mar 11 2010;464(7286):287-91.  
20 doi:10.1038/nature08799
- 21 31. Milev MP, Graziano C, Karall D, *et al.* Bi-allelic mutations in TRAPPC2L result in a  
22 neurodevelopmental disorder and have an impact on RAB11 in fibroblasts. *J Med Genet.* Nov  
23 2018;55(11):753-764. doi:10.1136/jmedgenet-2018-105441
- 24 32. Saad AK, Marafi D, Mitani T, *et al.* Biallelic in-frame deletion in TRAPPC4 in a family  
25 with developmental delay and cerebellar atrophy. *Brain.* Oct 1 2020;143(10):e83.  
26 doi:10.1093/brain/awaa256
- 27 33. Ghosh SG, Scala M, Beetz C, *et al.* A relatively common homozygous TRAPPC4  
28 splicing variant is associated with an early-infantile neurodegenerative syndrome. *Eur J Hum*  
29 *Genet.* Feb 2021;29(2):271-279. doi:10.1038/s41431-020-00717-5

- 1 34. Mohamoud HS, Ahmed S, Jelani M, et al. A missense mutation in TRAPPC6A leads to  
2 build-up of the protein, in patients with a neurodevelopmental syndrome and dysmorphic  
3 features. *Sci Rep*. Feb 1 2018;8(1):2053. doi:10.1038/s41598-018-20658-w
- 4 35. Bodnar B, DeGruttola A, Zhu Y, et al. Emerging role of NIK/IKK2-binding protein  
5 (NIBP)/trafficking protein particle complex 9 (TRAPPC9) in nervous system diseases. *Transl*  
6 *Res*. Oct 2020;224:55-70. doi:10.1016/j.trsl.2020.05.001
- 7 36. Kakar N, Goebel I, Daud S, et al. A homozygous splice site mutation in TRAPPC9  
8 causes intellectual disability and microcephaly. *Eur J Med Genet*. Dec 2012;55(12):727-31.  
9 doi:10.1016/j.ejmg.2012.08.010
- 10 37. Santos-Cortez RLP, Khan V, Khan FS, et al. Novel candidate genes and variants  
11 underlying autosomal recessive neurodevelopmental disorders with intellectual disability. *Hum*  
12 *Genet*. Sep 2018;137(9):735-752. doi:10.1007/s00439-018-1928-6
- 13 38. Wang X, Wu Y, Cui Y, Wang N, Folkersen L, Wang Y. Novel TRAPPC11 Mutations in  
14 a Chinese Pedigree of Limb Girdle Muscular Dystrophy. *Case Rep Genet*. 2018;2018:8090797.  
15 doi:10.1155/2018/8090797
- 16 39. Milev MP, Grout ME, Saint-Dic D, et al. Mutations in TRAPPC12 Manifest in  
17 Progressive Childhood Encephalopathy and Golgi Dysfunction. *Am J Hum Genet*. Aug 3  
18 2017;101(2):291-299. doi:10.1016/j.ajhg.2017.07.006

19

20 **Figure 1 Clinical features of patients with TRAPPC6B variants. A:** Phenogram of frequency  
21 of phenotypic features for 29 new patients and 8 previously reported patients (**Supplementary**  
22 **Table 1**). ID/DD=intellectual disability/developmental disability). Fields with missing data were  
23 not included in calculations for that feature. Behavioral phenotypes include aggression, self-  
24 injury, anxiety, and hyperactivity. **B-N:** Photos of dysmorphic features. No unifying dysmorphic  
25 features were observed. **B-C:** Patient 1 (Family 1) has gingival hypertrophy and swan neck  
26 deformity of fingers, representing dystonia. Patient also exhibited spastic-dystonic quadriplegia  
27 with contractures in the elbow flexors and plantar flexors, temporal wasting, muscle atrophy, and  
28 curling of all her toes (not shown). **C:** Patient 2 (Family 1) has synophrys, bitemporal narrowing,  
29 prominent cheekbones, a wide nasal root and bridge, and a papular lesion suspicious for an

1 occult encephalocele. Patient also exhibited spastic-dystonic quadriplegia, brachycephaly,  
 2 trigonocephaly, temporal wasting and muscle atrophy in his proximal limb muscle (not shown).  
 3 **E:** Patient 5 (Family 4) has microcephaly, bitemporal narrowing, low anterior hairline, deep-set  
 4 eyes, prominent ears, long nose with narrow nasal bridge, prognathia. **F:** Patient 6 (Family 4) has  
 5 microcephaly, bitemporal narrowing strabismus, positional plagiocephaly, deep set eyes, broad  
 6 nasal root and narrow nasal bridge, and widely spaced teeth. **G:** Patient 7 (Family 5) showing  
 7 depressed nasal bridge, upturned nasal tip, and thin upper lip. Patient also exhibited bilateral  
 8 clinodactyly, tapered fingers, and inverted nipples (not shown). **H-I:** Patient 10 (Family 8) has  
 9 microcephaly, long face, arched eyebrows, wide spaced eyes, almond shaped eye, straight nasal  
 10 bridge, broad nose, broad chin, and low set ears. Patient also exhibited arachnodactyly (not  
 11 shown). **J-K:** Patient 17 (Family 11) has narrow nasal bridge, posteriorly rotated ears. **L:** Patient  
 12 18 (Family 11) has upslanting palpebral fissures, square nasal tip. **M-N:** Patient 19 (Family 12)  
 13 has microcephaly, bulbous nasal tip, and creased earlobe.

14

15 **Figure 2 Qualitative and quantitative analysis of the MRI images. A, C, E, G, I, K:** Sagittal  
 16 MRI T1 weighted midline images. **B, H:** Axial FLAIR images. **D, F, J, L:** Axial MRI T2  
 17 weighted images. **A-B:** Patient 3, Family 2: 13-year-old female. **A.** Small craniofacial ratio,  
 18 thinning/foreshortening of the corpus callosum with greater involvement of the posterior fibers  
 19 (red arrow). **B:** Patchy FLAIR signal hyperintensity in the bilateral periventricular white matter  
 20 (arrows) extending to the centrum semiovale, peri Rolandic and peri atrial regions (not shown).  
 21 **C-D:** Patient 5, Family 4: 13-year-old female. **C.** Small craniofacial ratio, diffuse  
 22 thinning/foreshortening of the corpus callosum (red arrow), and brainstem and cerebellum  
 23 volume loss (cyan arrow). **D:** Abnormal angulation of the posterior margins of the ventricles  
 24 (arrows). **E-F:** Patient 6, Family 4: 9-year-old female. **E.** Small craniofacial ratio,  
 25 thinning/foreshortening of the corpus callosum and posterior greater than anterior parenchymal  
 26 loss (arrow). **F:** Diffuse parenchymal loss with preferential involvement of the posterior lobes,  
 27 ex-vacuo dilatation and angulation of the ventricles (arrows). **G-H.** Patient 13, Family 10: 6-  
 28 year-old male. **G.** Reduced FOD (frontal occipital diameter) diffuse thinning and foreshortening  
 29 of the corpus callosum (arrow). **H.** Patchy FLAIR signal hyperintensity in peri atrial white matter  
 30 associated with abnormal square shape of the posterior margins of the lateral ventricles (arrows).  
 31 **I-J.** Patient 14, Family 10: 2-year-old female. **I.** Reduced FOD, diffuse thinning and



1 foreshortening of the corpus callosum (arrow). **J.** Increased T2 signal in peri atrial white matter  
 2 associated with abnormal angulation of the posterior margins of the lateral ventricles (arrows).  
 3 **K-L.** Patient 16, Family 10: 5-year-old female. **K.** Marginal FOD (red arrow) and inferior vermis  
 4 hypoplasia (cyan arrow). **L.** No signal abnormalities present. **M.** Phenogram of MRI features for  
 5 16 new patients and 7 previously reported patients with MRI interpretation. Patient-specific  
 6 details are provided in **Supplemental Table 1**. VM=ventriculomegaly. WMI=white matter  
 7 hyperintensity or abnormalities. CC=corpus callosum. CB=cerebellum. CTX=cortex. **N.** Box and  
 8 whisker plot of six structural measures quantified from brain MRI volumes of 6 patients,  
 9 represented as Z scores, in comparison to an age-matched control cohort of typically developing  
 10 children. The threshold for significance of -1 SD indicates reduced volume compared to the  
 11 general population. Volume loss was identified in the cerebellum (CB), but there was no  
 12 consistent reduction in other measurements. Ventricle asymmetry (Vent) measures laterality of  
 13 ventricle expansion; no asymmetry was detected. Boxes represent 25th and 75th percentiles with  
 14 median line; whiskers represent data range. GM=grey matter, DGM=deep grey matter,  
 15 CB=cerebellum, WM=white matter, CC=corpus callosum, Vent=ventricle asymmetry.

16

17 **Figure 3 TRAPPC6B variants affect the stability of TRAPP II.** TRAPPC6B (wild type or the  
 18 p.Q152\* variant), were cloned into either pGADT7 (**A**) or pGBKT7 (**B**), TRAPPC2L and  
 19 TRAPPC3 were cloned into either pGBKT7 (**A**) or pGADT7 (**B**) and transformed into haploid  
 20 yeast cells. In some cases, an empty vector was used (indicated as $\Phi$ ). The cells were mated,  
 21 diploids selected and then spotted as serial dilutions on plates lacking leucine and tryptophan  
 22 (DDO) or plates lacking leucine, tryptophan and histidine (TDO). **C.** Fibroblasts from control or  
 23 affected individuals from family 15 (p.Q152\*) were lysed and probed for the indicated TRAPP  
 24 proteins or for tubulin as a loading control.

25

26 **Figure 4 TRAPPC6B Preferentially Associates with the TRAPP II Complex.** **A.** HeLa cells  
 27 were either untransfected (NT) or co-transfected with TRAPPC6A-V5/TRAPPC10-FLAG,  
 28 TRAPPC6A-V5/TRAPPC11-FLAG, TRAPPC6B-V5/TRAPPC10-FLAG, or TRAPPC6B-  
 29 V5/TRAPPC11. After 48 hours the cells were lysed and treated with anti-FLAG IgG agarose  
 30 beads. The eluates from the immunoprecipitation were probed for V5, FLAG and Tubulin. The

1 blot is representative of at least three biological replicates. Inputs represent 10% of the sample  
2 subjected to immunoprecipitation. **B.** Quantification of the ratio of V5 immunoprecipitated with  
3 FLAG from three different experiments. The integrated density of V5, FLAG and background  
4 nearby for each band was measured using ImageJ v1.53. To obtain the corrected integrated  
5 density, the background value for each band was subtracted. The V5/FLAG ratio was then  
6 calculated using the corrected integrated densities and normalized to the highest signal detected  
7 for FLAG.

8


9 **Figure 5 Fibroblasts from individuals with TRAPPC6B variants display membrane**  
10 **trafficking defects and have fragmented Golgi. A.** Fibroblasts from families 4 (c.149+2 T>A  
11 splice-site; Patients 5 and 6) and 15 (p.Q152\*; Patients 23 and 24) were transfected with ST-GFP  
12 and incubated overnight. The next day, cells were treated with 60  $\mu$ M biotin and imaged every 2  
13 minutes. Golgi-associated fluorescence was quantified and plotted as a function of time. In some  
14 cases, TRAPPC6B-RFP was co-transfected to verify a rescue of the trafficking defect. The error  
15 bars represent the SEM (standard error of the mean) at each time point. **B.** Representative images  
16 used for quantification of the RUSH trafficking assay at 0, 10, 20 and 30 minutes. N values  
17 ranged from 48-61 and come from at least three biological replicates. The scale bar represents 10  
18  $\mu$ m. **C.** Fibroblasts were either un-transfected or transfected with TRAPPC6B-RFP, fixed and  
19 stained for mannosidase II as a Golgi marker. The mannosidase II-positive structures were  
20 quantified as described in the methods section. Bars represent SEM. N values ranged from 65-82  
21 and come from at least three biological replicates. **D.** Representative images used for the  
22 quantifying the number of Golgi fragments. The scale bar represents 10  $\mu$ m.

23

24 **Figure 6 Neuronal TRAPPC6B knockdown impairments in a *Drosophila* model. A.** Box and  
25 whisker plot of distance traveled in 3 seconds in negative geotaxis assay comparing Gal4 and  
26 UAS driver heterozygotes and shRNA neuronal-driven expression for TRAPPC6B knockdown.  
27 Statistics determined using paired t-test (n=16 trials). Boxes represent 25th and 75th percentiles  
28 with median line; whiskers represent range of data.\* p<0.01, \*\* p<0.001. **B.** Erect wing  
29 phenotype is significantly increased in TRAPPC6B knockdown compared to heterozygous

1 controls. (n=113-137 flies/genotype). Statistics determined both as a 3-way and pairwise against  
2 individual controls using Chi-squared analysis. \* p<0.01.

3



4

*Figure 1*  
165x166 mm (x DPI)

5





Figure 2  
154x187 mm (x DPI)



**Figure 3**  
146x169 mm (x DPI)

1






Figure 4  
165x55 mm (x DPI)

ACCEPTED MANUSCRIPT




Figure 5  
165x163 mm (x DPI)




Figure 6  
89x59 mm (x DPI)

1  
2

Table I TRAPP genes with neurological disease connections

Gene (OMIM#*), citation	Complex	Disease	Cognitive findings	Epilepsy	Movement disorder	White matter	Brain volume	Language	Dysmorphic features	Visual system	Muscle findings
TRAPPC6B (#617862), this study	II, III	NEDMEBA	ID	Variable	Spasticity, dystonia, stereotypies	Thin corpus callosum, hyperintensity	Brain volume loss, microcephaly	Absent expressive language	Variable	No impairments	Reduced bulk
TRAPPC2L (#618331) <sup>12,31</sup>	II, III	PEERB	ID	Focal seizures and status epilepticus with infection	Tetraplegia; dystonia	Normal-delayed myelination	Variable atrophy	Absent speech	NR	Cerebral visual impairment	Rhabdomyolysis; Nonspecific biopsy
TRAPPC4 (#618741) <sup>15,32,33</sup>	II, III	NEDEBA	Normal-severe ID; regression	Yes	Spasticity; axial hypotonia; variable dyskinesia	White matter loss	Mild-severe cerebral atrophy; secondary microcephaly	Delay and loss of expressive language	Yes	Visual impairments; variable cataracts	Amyotrophy
TRAPPC6A (#610396) <sup>34</sup>	II, III	NDD	ID	NR	NR	NR	NR	Speech delay	Yes	NR	NR
TRAPPC9 (#613192) <sup>35,36</sup>	II	MRT13	Moderate-severe ID	Variable seizures	Hypotonia, stereotypies	Thin corpus callosum, reduced white matter	Postnatal microcephaly	Speech disorder	Yes	NR	NR
TRAPPC10 (#602103) <sup>24,37</sup>	II	NDD	Severe ID	Variable seizures	Hypotonia, waddling gait	1 patient thin corpus callosum	Microcephaly	Poor speech	NR	Low frequency strabismus	NR
TRAPPC11 (#615356)	III	LGMD	Normal-	Variable (general)	Some with	Some reduced	Normal-microcep	NR	NR	Variable (amblyo)	Limb girdle muscular



<sup>38</sup>			severe ID	ized seizures)	ataxia and/or choreiform movements	volume	haly; some cerebral atrophy			pia, cataract)	dystrophy
TRAPPC12 (#617669) <sup>39</sup>	III	PEBAS	Severe DD and regression	Seizures; myoclonus	Spasticity; truncal hypotonia; dystonia	Corpus callosum agenesis; hyperintensity	Microcephaly; pons hypoplasia; diffuse atrophy	NR	NR	Optic atrophy; cortical visual impairment	NR

1 ID = intellectual disability; LGMD = limb girdle muscular dystrophy; MRT13 = mental retardation, autosomal recessive 13; NDD =  
 2 neurodevelopmental disorder; NEDESBA = Neurodevelopmental disorder with epilepsy, spasticity, and brain atrophy; NEDMEBA =  
 3 neurodevelopmental disorder with microcephaly, epilepsy, and brain atrophy; NR = not reported; PEBAS = progressive encephalopathy with  
 4 brain atrophy and spasticity; PEERB progressive encephalopathy with episodic rhabdomyolysis. # = phenotype MIM number. \* = gene/locus MIM  
 5 number.  
 6  
 7

**Table 2 Clinical features of TRAPPC6B patients**

Family	Patient	W	S	G	V	S	S	Cont	Dy	R	Mus	Stere	Micro	Facial	Hand/	Othe	ID/	A	Beh
		alk	it	M	er	ez	pas	ractur	stonia	eflex	cle	otopies	cephaly	feat.	foot	r organ	GD	S	avioral
				FS	bal	iz	t.	res	nia	x	loss	es	y			n	D	D	
1	1	+	+	5	+	+	+	+	+	-	+	+	Yes	+	0	0	+	0	0
	2	+	+	5	+	+	+	+	+	0	+	+	Yes	+	0	0	+	0	0
2	3	+	+	5	+	+	+	+	0	+	N/A	+	Yes, prog.	+	+	0	+	N/A	0
3	4	+	0	N/A	+	+	+	+	+	N/A	N/A	+	-3 SD 35y	+	+	0	+	N/A	+
4	5	+	0	4	+	+	0	0	0	+	+	+	-6.5 SD 15y	+	+	0	+	N/A	0
	6	+	+	5	+	0	0	+	0	+	+	+	-6 SD 11y	+	+	+	+	N/A	0
5	7	0	0	3	+	0	0	0	0	0	N/A	+	No, -1.3 SD 3.5y	+	0	+	+	0	+
6	8	0	0	2	+	0	0	0	0	0	N/A	+	-2.5 SD 5y	+	+	+	+	0	0
7	9	0	0	N/A	+	0	+	0	0	0	+	+	-2 SD birth	+	0	0	+	N/A	0
8	10	+	0	N/A	+	+	Yes	0	0	+	N/A	+	-2 SD birth	+	+	0	+	+	+
	11	0	0	N/A	+	0	0	0	0	0	N/A	+	-2 SD 4y4m	0	0	+	+	+	+
10	12	0	0	N/A	N/A	0	0	0	0	0	N/A	N/A	-2 SD	0	0	0	+	+	+
	13	0	0	N/A	+	+	0	0	0	N/A	N/A	N/A	-5.2 SD 11y	+	0	0	+	+	0
	14	0	0	N/A	+	0	0	0	0	N/A	N/A	N/A	-5.7 SD 6y	0	0	0	+	+	0
	15	+	0	N/A	+	0	0	0	0	N/A	N/A	N/A	-2.4 SD 14m	0	0	0	+	+	0
11	16	0	0	N/A	+	0	0	0	0	N/A	N/A	N/A	N/A	0	0	0	+	0	0
	17	+	0	N/A	+	0	Yes	+	0	0	N/A	+	N/A	0	0	0	+	N/A	0
12	18	0	0	N/A	+	0	0	+	0	0	N/A	+	Yes	0	0	0	+	N/A	0
	19	0	0	N/A	+	+	Yes	0	0	0	N/A	N/A	Yes	0	0	0	+	+	0
	20	+	0	N/A	+	0	0	0	0	0	N/A	0	Yes	0	0	0	+	N/A	0

13	21	+	0	4	N/A	+	+	N/A	0	N/A	N/A	+	-2 SD birth	+	+	0	+	+	0
14	22	0	0	N/A	N/A	+	Yes	+	0	+	N/A	+	-4.3 SD 5y	0	0	0	+	+	0
15	23	0	0	N/A	+	0	0	0	0	+	N/A	+	No -1.4 SD	0	0	0	+	+	+
	24	0	0	N/A	+	0	0	0	0	+	N/A	0	No -0.5 SD	0	0	+	+	0	0
16	25	0	0	N/A	+	0	+	+	+	+	0	+	-4.8 SD	+	0	+	+	+	+
	26	0	0	N/A	+	0	+	+	+	+	0	+	-4.8 SD	+	0	+	+	+	+
17	27	0	0	N/A	+	+	+	N/A	0	N/A	0	0	-2.4SD 30y	0	0	0	+	0	0
	28	0	0	N/A	+	+	+	N/A	0	N/A	0	0	-2.8 SD 30y	0	0	0	+	0	0
18	29	+	0	4	+	+	+	0	0	+	N/A	0	Yes, 46 cm	0	0	0	+	0	0

1 Symbols describing features: + defects present; 0=no abnormalities; N/A data not available. Facial features include bitemporal narrowing,  
2 narrow nasal bridge, deep/wide-set eyes. Hand or foot features include syndactyly, tapered, thin, or hypoplastic digits, and arachnodactyly  
3 affecting either the hands and/or feet. Other organs include cardiac, genito-urinary, liver, and eye. Behavioral concerns include anxiety, self-  
4 injury, hyperactivity, and aggression. Walking (0=walks unassisted, += walks with assistance or gait impairment present, ++=cannot walk) Sitting  
5 (0=sits without support, +=sit with support, ++=cannot sit); Verbal (0=normal speech, +=impaired age-appropriate expressive language); Seiz.  
6 (0=no seizures, +=only 1 seizure in medical history, ++=epilepsy); Spasticity (0=none, +=lower limbs only, ++=upper+lower body involvement);  
7 Dystonia (0=no, +=generalized affecting  $\geq 2$  limbs); Reflex (-=absent knee-jerk reflex, 0=normal, +=exaggerated/brisk) Muscle loss (0= none,  
8 +=atrophy or reduced bulk with or without hypotonia) Autism (0=no, +=yes. N/A may also refer to inability to assess due to ID severity).